Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:CTRV
Delisted

ContraVir Pharmaceuticals Inc Stock Price (Quote)

$1.23
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $1.23 $1.23 Friday, 27th May 2022 CTRV stock ended at $1.23. During the day the stock fluctuated 0% from a day low at $1.23 to a day high of $1.23.
90 days $0.94 $1.27
52 weeks $0.86 $2.32

Historical ContraVir Pharmaceuticals Inc prices

Date Open High Low Close Volume
Nov 04, 2016 $1,159.20 $1,169.84 $1,092.00 $1,103.20 748
Nov 03, 2016 $1,103.20 $1,148.00 $1,092.00 $1,148.00 1 058
Nov 02, 2016 $1,181.60 $1,327.20 $1,097.60 $1,114.40 5 052
Nov 01, 2016 $1,114.40 $1,170.40 $1,075.20 $1,159.20 1 584
Oct 31, 2016 $1,075.20 $1,159.20 $1,024.80 $1,131.20 2 214
Oct 28, 2016 $1,036.00 $1,092.00 $1,019.20 $1,080.80 956
Oct 27, 2016 $1,080.80 $1,092.00 $1,036.00 $1,052.80 547
Oct 26, 2016 $1,108.80 $1,125.04 $1,019.20 $1,103.20 2 200
Oct 25, 2016 $1,047.20 $1,310.40 $1,030.40 $1,136.80 8 498
Oct 24, 2016 $1,030.40 $1,052.80 $935.20 $1,041.60 2 618
Oct 21, 2016 $1,125.60 $1,207.36 $1,013.60 $1,052.80 4 333
Oct 20, 2016 $1,198.40 $1,260.00 $1,148.00 $1,198.40 2 706
Oct 19, 2016 $1,293.60 $1,338.40 $1,136.80 $1,198.40 9 084
Oct 18, 2016 $1,265.60 $1,394.40 $1,209.60 $1,316.00 20 088
Oct 17, 2016 $1,008.00 $1,484.00 $991.20 $1,310.40 54 544
Oct 14, 2016 $812.00 $1,142.40 $789.60 $1,097.60 36 163
Oct 13, 2016 $800.80 $845.60 $700.00 $761.60 12 432
Oct 12, 2016 $649.60 $649.60 $621.60 $627.20 83
Oct 11, 2016 $638.40 $683.20 $621.60 $655.20 151
Oct 10, 2016 $660.80 $672.00 $616.00 $621.60 169
Oct 07, 2016 $632.80 $672.00 $621.60 $672.00 68
Oct 06, 2016 $644.00 $649.60 $627.20 $638.40 54
Oct 05, 2016 $638.40 $694.40 $621.60 $638.40 550
Oct 04, 2016 $616.00 $649.60 $616.00 $616.00 113
Oct 03, 2016 $604.80 $627.20 $604.80 $610.40 101
Click to get the best stock tips daily for free!

About ContraVir Pharmaceuticals Inc

ContraVir Pharmaceuticals ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. Contr... CTRV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT